Nuron Biotech

About Nuron Biotech

Nuron Biotech, founded in 2009 by Shankar Musunuri, Vithalbhai Dhaduk, and David Zeng, was a specialty biologics and vaccines company headquartered in Exton, Pennsylvania. The company is now considered deadpooled.

The leadership team, including CEO Shankar Musunuri and SVP David Zeng, brought extensive experience from the pharmaceutical sector. Musunuri, prior to establishing Nuron, spent nearly 15 years at Pfizer, where he played a significant role in the global launch of the vaccine Prevnar 13. His background in pharmaceutical sciences and business administration informed the company's strategy of acquiring and developing a mixed portfolio of commercial-stage and clinical assets.

Nuron Biotech's business model centered on developing and marketing vaccines and biologics for neurodegenerative and infectious diseases. The company pursued a dual strategy: generating revenue from established commercial vaccines while simultaneously investing in a pipeline of new drug candidates. This involved acquiring assets from major pharmaceutical firms, such as Pfizer and its subsidiary Wyeth. A key part of its funding was a significant financing deal with HealthCare Royalty Partners, which included an equity investment and a royalty agreement tied to future sales of its vaccine products.

The company's portfolio was diverse. It acquired the commercial rights to Meningitec, a vaccine for meningitis C, from Pfizer, which was registered in 23 countries. Another significant acquisition was HibTITER, a pediatric vaccine for Haemophilus influenzae type b, which it purchased from Wyeth with plans to re-launch it. The development pipeline featured NU100, a proprietary interferon beta-1b formulation for treating multiple sclerosis that had advanced to Phase 3 clinical trials. Nuron also in-licensed vaccine candidates for Alzheimer's disease and Hepatitis B and C, aiming to address significant unmet medical needs.